HALO Halozyme Therapeutics Inc.
4,461
$45.11
$0.28
(0.62%)
| Watchers | 4,461 |
| 52-Wk Low | $31.86 |
| 52-Wk High | $46.16 |
| Market Cap | $5.78B |
| Volume | 47,900.00 |
| 52-Wk High | $46.16 |
| 52-Wk Low | $31.86 |
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbPR Newswire • 8 days ago
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
Share to Feed
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
Halozyme to Participate in Upcoming Investor Conferences Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, May 8, 2024 SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme...
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire SAN DIEGO, May 7, 2024 Revenue Increased 21% YOY to...
Mahesh Krishnan Elected to Halozyme's Board of Directors Mahesh Krishnan Elected to Halozyme's Board of Directors PR Newswire SAN DIEGO, April 25, 2024 SAN DIEGO, April 25, 2024 /PRNewswire...
Latest Ratings for HALO
DateFirmActionFromTo Nov 2021Wells FargoMaintainsOverweight Nov 2021JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkMaintainsOutperform
View More Analyst...
It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 12.5% in that time frame, underperforming the S&P 500.Will the recent negative...
A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have added about 2.8% in that time frame, underperforming the S&P 500.Will the recent positive trend...
Investors in Halozyme Therapeutics Inc (HALO) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO...
Halozyme Therapeutics, Inc. (NASDAQ:HALO Free Report) Equities researchers at Zacks Research lifted their Q1 2025 EPS estimates for Halozyme Therapeutics in a research report issued...